G7mAb

G7mAb is a **monoclonal antibody** generated via hybridoma technology that targets CD24, a glycosylated cell surface protein highly expressed on various cancer cells, notably hepatocellular carcinoma (HCC) and some breast cancers. G7mAb binds strongly to CD24 and is designed to reduce immunogenicity, allowing for higher stability and safety in human applications. Its mechanism centers on binding membrane CD24, leading to immune cell-mediated lysis of tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC) and promoting recruitment of peripheral blood mononuclear cells and natural killer (NK) cells to attack cancer cells. The antibody has been humanized to produce hG7-BM3, maintaining its affinity and specificity while further reducing immunogenicity. G7mAb has also served as a backbone in development of antibody-drug conjugates (ADCs), such as hG7-BM3-VcMMAE, which links a cytotoxic payload to the antibody for enhanced tumor cell killing via targeted delivery. G7mAb has been used to create combination chimeric molecules and fusion proteins for specialized tumor targeting and immune recruitment.